| (CCTG) IND.214 | A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients With Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours | Hotte, Dr Sebastien | Open | NCT02285816 |
| (CCTG) IND.228 | A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours | Hirte, Dr Hal | Open | NCT02879162 |
| (Medivation) MDV3800-01 / TRIO031 | A Phase I Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) in Patients With Advanced Solid Tumors and Normal or Varying Degrees of Renal Impairment | Hirte, Dr Hal | Open | NCT02997163 |
| (Medivation) MDV3800-13 | A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib | Hirte, Dr Hal | Open | NCT02921919 |
Find a Trial
Contact Us